Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
We get it from animal-based food or supplements
2025;41(6):1989-2001.e1
I love this stuff
TB-500 Side by Side | Feature | BPC-157 | TB-500 | |---|---|---| | Amino acid length | 15 | 43 (full T beta-4) / ~7 (synthetic fragment) | | Endogenous homolog | None confirmed | Thymosin beta-4 (ubiquitous) | | Primary mechanism | eNOS activation, VEGFR2 upregulation, FAK-paxillin | G-actin sequestration, NF-kB suppression | | Strongest preclinical signal | Tendon, gut, peripheral nerve | Cardiac, corneal, dermal wound | | Human RCT data | Minimal (IBD, Phase II, unpublished) | Limited (EB, dry eye, small N) | | WADA prohibited | Yes (S2) | Yes (S2) | | FDA compounding status | Bulk substance under review | Similar gray zone | | Typical dose | 250 to 500 mcg/day SC/IM | 2 to 5 mg twice weekly SC/IM | Clinical Scenarios Where Prescribers Encounter These Compounds Chronic Tendinopathy A 38-year-old recreational athlete with 6-month Achilles tendinopathy refractory to physical therapy and eccentric exercise asks about BPC-157
US$ 22.04
US$ 23.90
US$ 26.05
US$ 23.05
US$ 24.42
US$ 23.25
